Etelcalcetide, A Novel Calcimimetic, Prevents Vascular Calcification in A Rat Model of Renal Insufficiency with Secondary Hyperparathyroidism-Reference-Cited by-同舟云学术

Etelcalcetide, A Novel Calcimimetic, Prevents Vascular Calcification in A Rat Model of Renal Insufficiency with Secondary Hyperparathyroidism

Published:2017-10-16 Issue:6 Volume:101 Page:641-653
ISSN:0171-967X
Container-title:Calcified Tissue International
language:en
Short-container-title:Calcif Tissue Int

Author:

Yu Longchuan,Tomlinson James E.,Alexander Shawn T.,Hensley Kelly,Han Chun-Ya,Dwyer Denise,Stolina Marina,Dean Charles,Goodman William G.,Richards William G.,Li Xiaodong

Funder

Amgen

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology,Orthopedics and Sports Medicine,Endocrinology, Diabetes and Metabolism

Link

http://link.springer.com/article/10.1007/s00223-017-0319-7/fulltext.html

Reference53 articles.

1. Paloian NJ, Giachelli CM (2014) A current understanding of vascular calcification in CKD. Am J Physiol Renal Physiol 307:F891–F900

2. Shroff R, Long DA, Shanahan C (2013) Mechanistic insights into vascular calcification in CKD. J Am Soc Nephrol 24:179–189

3. Raggi P, Chertow GM, Torres PU, Csiky B, Naso A, Nossuli K, Moustafa M, Goodman WG, Lopez N, Downey G, Dehmel B, Floege J, Advance Study Group (2011) The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant 26:1327–1339

4. Urena-Torres PA, Floege J, Hawley CM, Pedagogos E, Goodman WG, Petavy F, Reiner M, Raggi P (2013) Protocol adherence and the progression of cardiovascular calcification in the ADVANCE study. Nephrol Dial Transplant 28:146–152

5. Moe SM, Chertow GM, Parfrey PS, Kubo Y, Block GA, Correa-Rotter R, Drueke TB, Herzog CA, London GM, Mahaffey KW, Wheeler DC, Stolina M, Dehmel B, Goodman WG, Floege J, Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events Trial Investigators (2015) Cinacalcet, fibroblast growth factor-23, and cardiovascular disease in hemodialysis: the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial. Circulation 132:27–39

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multiscale effects of the calcimimetic drug, etelcalcetide on bone health of rats with secondary hyperparathyroidism induced by chronic kidney disease;Bone;2024-08

2. FDA's stamp of approval: Unveiling peptide breakthroughs in cardiovascular diseases, ACE, HIV, CNS, and beyond;Journal of Peptide Science;2024-06-17

3. Antiosteoporosis medications and cardiovascular disease: a population-based nationwide nested case–control study;Frontiers in Pharmacology;2023-10-10

4. Cinacalcet use in secondary hyperparathyroidism: a machine learning-based systematic review;Frontiers in Endocrinology;2023-07-19

5. Upacicalcet, a positive allosteric modulator of the calcium-sensing receptor, prevents vascular calcification and bone disorder in a rat adenine-induced secondary hyperparathyroidism model;Bone;2023-02